Anti-IgE for the Treatment of Chronic Urticaria

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi:10.1111/all.13397
   PubMed Web of Science ®Google Scholar
• Wedi B. Urticaria and angioedema. In: Plewig G, French L, Ruzicka T, Kaufmann R, Hertl M, editors. Braun-falco’s dermatologe. Berlin, Heidelberg: Springer Germany; 2020. doi:10.1007/978-3-662-58713-3_29-1.
   Google Scholar
• Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205–217. doi:10.1038/nri2273
   PubMed Web of Science ®Google Scholar
• Gomez G. Current strategies to inhibit high affinity FcepsilonRI-mediated signaling for the treatment of allergic disease. Front Immunol. 2019;10:175. doi:10.3389/fimmu.2019.00175
   PubMed Web of Science ®Google Scholar
• Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of “real-world” evidence. JAMA Dermatol. 2019;155(1):29–38. doi:10.1001/jamadermatol.2018.3447
   PubMed Web of Science ®Google Scholar
• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi:10.1111/all.14037
   PubMed Web of Science ®Google Scholar
• Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium internationale allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(5):321–333. doi:10.1159/000507218
   PubMed Web of Science ®Google Scholar
• Baiardini I, Canonica GW, La Grutta S, Braido F. Clinically significant differences in patient-reported outcomes evaluations in chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2020;20(3):261–267. doi:10.1097/ACI.0000000000000636
   Web of Science ®Google Scholar
• Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria. Allergy. 2019;74(12):2550–2553. doi:10.1111/all.13878
   Web of Science ®Google Scholar
• Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16(12):1196–1208.
   PubMed Web of Science ®Google Scholar
• Schoepke N, Asero R, Ellrich A, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study. Allergy. 2019;74(12):2427–2436. doi:10.1111/all.13949
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Schmetzer O, Scheffel J, Church MK. Immunoglobulin E-mediated autoimmunity. Front Immunol. 2018;9:689. doi:10.3389/fimmu.2018.00689
   PubMed Web of Science ®Google Scholar
• Wedi B. Ligelizumab for the treatment of chronic spontaneous urticaria. Expert Opin Biol Ther. 2020;20(8):853–861. doi:10.1080/14712598.2020.1767061
   PubMed Web of Science ®Google Scholar
• Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase–a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794. doi:10.1371/journal.pone.0014794
   PubMed Web of Science ®Google Scholar
• Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–882.
   PubMed Web of Science ®Google Scholar
• Altrichter S, Schumacher P, Alraboni O, et al. Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients. Clin Transl Allergy. 2020;10(1):18–z. doi:10.1186/s13601-020-00324-z
   Web of Science ®Google Scholar
• Takahagi S, Tanaka A, Hide M. Sweat allergy. Allergol Int. 2018;67(4):435–441.
   Web of Science ®Google Scholar
• Giménez-Arnau AM, Salman A. Targeted therapy for chronıc spontaneous urtıcarıa: ratıonale and recent progress. Drugs. 2020;80(16):1617–1634. doi:10.1007/s40265-020-01387-9
   Web of Science ®Google Scholar
• Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354(25):2689–2695.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):CD003559.
   PubMed Web of Science ®Google Scholar
• Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI biologicals guidelines. Allergy. 2020. doi:10.1111/all.14547
   Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.
   PubMed Web of Science ®Google Scholar
• Urgert MC, van den Elzen MT, Knulst AC, Fedorowicz Z, van Zuuren EJ. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. Br J Dermatol. 2015;173(2):404–415. doi:10.1111/bjd.13845
   PubMed Web of Science ®Google Scholar
• Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):1742–1750.e4.
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567–73.e1. doi:10.1016/j.jaci.2011.06.010
   PubMed Web of Science ®Google Scholar
• Lieberman PL, Jones I, Rajwanshi R, Rosén K, Umetsu DT. Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics. J Allergy Clin Immunol. 2017;140(6):1734–1736.e4.
   Web of Science ®Google Scholar
• EMA XOLAIR EPAR assessment report; 2020. Available from: https://www.ema.europa.eu/en/documents/variation-report/xolair-h-c-606-ii-0101-epar-assessment-report-variation_en.pdf. Accessed January 22, 2021.
   Google Scholar
• Deza G, March-Rodriguez A, Sanchez S, et al. Relevance of the basophil high-affinity IgE receptor in chronic urticaria: clinical experience from a tertiary care institution. J Allergy Clin Immunol Pract. 2019;7(5):1619–1626.e1.
   PubMed Web of Science ®Google Scholar
• Yalcin AD. Advances in anti-IgE therapy. Biomed Res Int. 2015;2015:317465. doi:10.1155/2015/317465
   PubMed Web of Science ®Google Scholar
• Deza G, Bertolin-Colilla M, Sanchez S, et al. Basophil FcvarepsilonRI expression is linked to time to omalizumab response in chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;141(6):2313–2316.e1.
   PubMed Web of Science ®Google Scholar
• Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–342. doi:10.1016/j.jaci.2014.04.036
   PubMed Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2018;73(3):576–584. doi:10.1111/all.13339
   PubMed Web of Science ®Google Scholar
• Bérard F, Le Bouedec F, Bouillet MC. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the Phase IV open-label SUNRISE study. Br J Dermatol. 2019;180(1):56–66. doi:10.1111/bjd.16904
   Web of Science ®Google Scholar
• Maurer M, Schutz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):870–873.e5.
   PubMed Web of Science ®Google Scholar
• Gastaminza G, Azofra J, Nunez-Cordoba JM, et al. Efficacy and safety of omalizumab (xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial. J Allergy Clin Immunol Pract. 2019;7(5):1599–1609.e1.
   PubMed Web of Science ®Google Scholar
• Metz M, Schutz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):864–867.e5.
   PubMed Web of Science ®Google Scholar
• Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649.
   PubMed Web of Science ®Google Scholar
• Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol. 2020;184(1):167–168. doi:10.1111/bjd.19425
   Web of Science ®Google Scholar
• Baena-Cagnani CE, Gómez RM. Current status of therapy with omalizumab in children. Curr Opin Allergy Clin Immunol. 2014;14(2):149–154. doi:10.1097/ACI.0000000000000044
   PubMed Web of Science ®Google Scholar
• Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33(4):e13489. doi:10.1111/dth.13489
   PubMed Web of Science ®Google Scholar
• Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. 2020;37(6):1051–1054. doi:10.1111/pde.14360
   PubMed Web of Science ®Google Scholar
• Kitsioulis NA, Xepapadaki P, Kostoudi S, Manousakis E, Douladiris N, Papadopoulos NG. Omalizumab in pediatric cold contact urticaria: warm blanket for a cold bath? Pediatr Allergy Immunol. 2016;27(7):752–755. doi:10.1111/pai.12609
   Web of Science ®Google Scholar
• Netchiporouk E, Nguyen CH, Thuraisingham T, Jafarian F, Maurer M, Ben-Shoshan M. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. 2015;26(6):585–588. doi:10.1111/pai.12407
   PubMed Web of Science ®Google Scholar
• Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatr Allergy Immunol. 2015;26(6):588–590. doi:10.1111/pai.12441
   Web of Science ®Google Scholar
• Arasi S, Crisafulli G, Caminiti L, et al. Treatment with omalizumab in a 16-year-old caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol. 2015;26(6):583–585. doi:10.1111/pai.12413
   Web of Science ®Google Scholar
• Saito J, Yakuwa N, Sandaiji N, et al. Omalizumab concentrations in pregnancy and lactation: a case study. J Allergy Clin Immunol Pract. 2020;8(10):3603–3604.
   Web of Science ®Google Scholar
• Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, Solé D. Omalizumab as third-line therapy for urticaria during pregnancy. J Investig Allergol Clin Immunol. 2017;27(5):326–327. doi:10.18176/jiaci.0179
   PubMed Web of Science ®Google Scholar
• Gonzalez P, Soriano V, Lopez P, Niveiro E. Anaphylaxis to proton pump inhibitors. Allergol Immunopathol (Madr). 2002;30(6):342–343. doi:10.1016/S0301-0546(02)79150-7
   Google Scholar
• Ghazanfar MN, Thomsen SF. Successful and safe treatment of chronic spontaneous urticaria with omalizumab in a woman during two consecutive pregnancies. Case Rep Med. 2015;2015:368053. doi:10.1155/2015/368053
   PubMedGoogle Scholar
• Cuervo-Pardo L, Barcena-Blanch M, Radojicic C. Omalizumab use during pregnancy for CIU: a tertiary care experience. Eur Ann Allergy Clin Immunol. 2016;48(4):145–146.
   PubMed Web of Science ®Google Scholar
• Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145(2):528–536.e1. doi:10.1016/j.jaci.2019.05.019
   PubMed Web of Science ®Google Scholar
• Pfaller B, Yepes-Nuñez JJ, Agache I, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy. 2020. doi:10.1111/all.14282
   Web of Science ®Google Scholar
• Levi-Schaffer F, Mankuta D. Omalizumab safety in pregnancy. J Allergy Clin Immunol. 2020;145(2):481–483.
   Web of Science ®Google Scholar
• EMA. Xolair. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xolair. Accessed March 22, 2020.
   Google Scholar
• Mandel VD, Guanti MB, Liberati S, Demonte A, Pellacani G, Pepe P. Omalizumab in chronic spontaneous urticaria refractory to conventional therapy: an italian retrospective clinical analysis with suggestions for long-term maintenance strategies. Dermatol Ther (Heidelb). 2018;8(2):291–301. doi:10.1007/s13555-018-0240-7
   Web of Science ®Google Scholar
• Zbiciak-Nylec M, Wcisło-Dziadecka D, Kasprzyk M, et al. Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria. Clin Exp Dermatol. 2018;43(5):525–528. doi:10.1111/ced.13368
   PubMed Web of Science ®Google Scholar
• Castagna J, Bernard L, Hacard F, et al. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria. Br J Dermatol. 2020;183(6):1124–1126. doi:10.1111/bjd.19312
   Web of Science ®Google Scholar
• Kocatürk E, Deza G, Kızıltaç K, Giménez-Arnau AM. Omalizumab updosing for better disease control in chronic spontaneous urticaria patients. Int Arch Allergy Immunol. 2018;177(4):360–364. doi:10.1159/000491530
   PubMed Web of Science ®Google Scholar
• Gu C, Upchurch K, Mamaril-Davis J, et al. Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma. Clin Exp Allergy. 2020;50(10):1196–1199. doi:10.1111/cea.13696
   Web of Science ®Google Scholar
• Jensen-Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy. 2017;72(6):866–887. doi:10.1111/all.13119
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Achatz G, Turner MC, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008;63(10):1255–1266. doi:10.1111/j.1398-9995.2008.01768.x
   PubMed Web of Science ®Google Scholar
• Ferastraoaru D, Bax HJ, Bergmann C, et al. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a position paper of the european academy of allergy and clinical immunology (EAACI). Clin Transl Allergy. 2020;10(1):32–w. doi:10.1186/s13601-020-00335-w
   Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–9.e6. doi:10.1016/j.jaci.2012.01.033
   PubMed Web of Science ®Google Scholar
• Johnston A, Smith C, Zheng C, et al. Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: a systematic review and meta-analysis. Clin Exp Allergy. 2019;49(10):1291–1305. doi:10.1111/cea.13457
   Web of Science ®Google Scholar
• Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice. Drug Des Devel Ther. 2019;13:3181–3186. doi:10.2147/DDDT.S214307
   PubMed Web of Science ®Google Scholar
• Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers. J Allergy Clin Immunol Pract. 2020;8(1):113–124.
   PubMed Web of Science ®Google Scholar
• Larenas-Linnemann D, Saini SS, Azamar-Jácome AA, Maurer M. Chronic urticaria can be caused by cancer and resolves with its cure. Allergy. 2018;73(7):1562–1566. doi:10.1111/all.13434
   Web of Science ®Google Scholar
• Asero R, Marzano AV, Ferrucci S, Cugno M. D-dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017;172(1):40–44. doi:10.1159/000453453
   PubMed Web of Science ®Google Scholar
• Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139(3):1059–1061.e1.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73(4):940–948. doi:10.1111/all.13352
   PubMed Web of Science ®Google Scholar
• Straesser MD, Oliver E, Palacios T, et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1386–1388.e1.
   Web of Science ®Google Scholar
• Asero R. Omalizumab in severe chronic urticaria: are slow and non-responders different? Eur Ann Allergy Clin Immunol. 2020;(online first). doi:10.23822/EurAnnACI.1764-1489.167
   Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;140(6):1749–1751.
   PubMed Web of Science ®Google Scholar
• Weller K, Ohanyan T, Hawro T, et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy. 2018;73(12):2406–2408. doi:10.1111/all.13586
   PubMed Web of Science ®Google Scholar
• Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2019;33(5):918–924. doi:10.1111/jdv.15350
   Web of Science ®Google Scholar
• Ghazanfar MN, Holm JG, Thomsen SF. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. J Eur Acad Dermatol Venereol. 2018;32(10):1761–1767. doi:10.1111/jdv.15045
   Web of Science ®Google Scholar
• Ertas R, Ozyurt K, Atasoy M, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705–712. doi:10.1111/all.13345
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract. 2020;8(1):318–325.e5.
   PubMed Web of Science ®Google Scholar
• de Montjoye L, Darrigade AS, Gimenez-Arnau A, Herman A, Dumoutier L, Baeck M. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2020. doi:10.23822/EurAnnACI.1764-1489.132
   Web of Science ®Google Scholar
• Hamilton RG. Monitoring allergic patients on omalizumab with free and total serum IgE measurements. J Allergy Clin Immunol Pract. 2016;4(2):366–368. doi:10.1016/j.jaip.2015.12.002
   PubMed Web of Science ®Google Scholar
• Ferrer M, Giménez-Arnau A, Saldana D, et al. Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: exploratory analysis. J Allergy Clin Immunol Pract. 2018;6(4):1191–1197.e5.
   PubMed Web of Science ®Google Scholar
• Romano C, Sellitto A, De Fanis U, et al. Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria. Ann Allergy Asthma Immunol. 2010;104(1):95–97. doi:10.1016/j.anai.2009.11.017
   PubMed Web of Science ®Google Scholar
• Silva PM, Costa AC, Mendes A, Barbosa MP. Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015;43(2):168–173.
   PubMed Web of Science ®Google Scholar
• Alizadeh Aghdam M, Pieterse RH, Kentie PA, Rijken F, Knulst AC, Rockmann H. Effective omalizumab interval prolongation in the treatment of chronic urticaria. J Allergy Clin Immunol Pract. 2020;8(10):3667–3668.e1.
   Web of Science ®Google Scholar
• Niemeyer-van der Kolk T, van Maaren MS, van Doorn MBA. Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(6):1992–1994.
   Web of Science ®Google Scholar
• Eghrari-Sabet J, Sher E, Kavati A, et al. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States. Allergy Asthma Proc. 2018;39(3):191–200. doi:10.2500/aap.2018.39.4132
   Web of Science ®Google Scholar
• Sussman G, Hébert J, Gulliver W, et al. Omalizumab re-treatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial. J Allergy Clin Immunol Pract. 2020;8(7):2372–2378.e5.
   PubMed Web of Science ®Google Scholar
• Har D, Patel S, Khan DA. Outcomes of using omalizumab for more than 1 year in refractory chronic urticaria. Ann Allergy Asthma Immunol. 2015;115(2):126–129.
   PubMed Web of Science ®Google Scholar
• Ensina LF, de Lacerda AE, Machado LM, Camelo-Nunes I, Solé D. Long-term omalizumab therapy for refractory chronic spontaneous urticaria: a real-life experience. Ann Allergy Asthma Immunol. 2015;115(6):536.
   Web of Science ®Google Scholar
• Kavati A, Zhdanava M, Ortiz B, et al. Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. Allergy Asthma Proc. 2019;40(5):321–328. doi:10.2500/aap.2019.40.4236
   PubMed Web of Science ®Google Scholar
• Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150(3):288–290. doi:10.1001/jamadermatol.2013.8705
   PubMed Web of Science ®Google Scholar
• Alizadeh Aghdam M, van den Broek F, Rijken F, Knulst AC, Rockmann H. High-dose omalizumab use in patients with chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;8(4):1426–1427.e1.
   Web of Science ®Google Scholar
• Curto-Barredo L, Spertino J, Figueras-Nart I, et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol. 2018;179(1):210–212. doi:10.1111/bjd.16379
   PubMed Web of Science ®Google Scholar
• Metz M, Vadasz Z, Kocaturk E, Gimenez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59(1):38–45. doi:10.1007/s12016-020-08794-6
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385. doi:10.1111/cea.12400
   PubMed Web of Science ®Google Scholar
• Jensen RK, Jabs F, Miehe M, et al. Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy. Allergy. 2020;75(8):1956–1965. doi:10.1111/all.14222
   PubMed Web of Science ®Google Scholar
• Maurer M, Gimenez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321–1332. doi:10.1056/NEJMoa1900408
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Baker D, Maurer M, et al. Ligelizumab achieves sustained control of chronic spontaneous urticaria symptoms of hives, itch and angioedema: 1-year treatment results. Allergy. 2019;74(S106):21. doi:10.1111/all.13957
   Google Scholar
• Soong W, Metz M, Bernstein JA, et al. Long-term treatment with ligelizumab achieves prolonged symptom control in patients with chronic spontaneous urticaria during the post-treatment follow-up. J Allergy Clin Immunol. 2020;145(2):AB341. doi:10.1016/j.jaci.2019.12.077
   Web of Science ®Google Scholar
• Maurer M, Giménez-Arnau AM, Soong W, et al. Treatment with ligelizumab achieves over forty percent higher complete response rate in chronic spontaneous urticaria patients originally treated with omalizumab. Allergy. 2020;75(S109):86. doi:10.1111/all.14504
   Google Scholar
• Severin T, Maurer M, Giménez-Arnau AM, et al. Study design and rationale of a phase 3b extension study of ligelizumab in adult and adolescent patients with chronic spontaneous urticaria. Allergy. 2020;75(S109):446. doi:10.1111/all.14508
   PubMed Web of Science ®Google Scholar
• Gasser P, Eggel A. Targeting IgE in allergic disease. Curr Opin Immunol. 2018;54:86–92.
   PubMed Web of Science ®Google Scholar
• Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun. 2016;7(1):11610. doi:10.1038/ncomms11610
   Web of Science ®Google Scholar
• Selb R, Eckl-Dorna J, Twaroch TE, et al. Critical and direct involvement of the CD23 stalk region in IgE binding. J Allergy Clin Immunol. 2017;139(1):281–289.e5.
   PubMed Web of Science ®Google Scholar
• Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975–9987. doi:10.1074/jbc.M117.776476
   PubMed Web of Science ®Google Scholar
• Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165–w. doi:10.1038/s41467-019-13815-w
   PubMed Web of Science ®Google Scholar
• Brightbill D, Lin Y, Lin Z. Quilizumab is an afucosylated humanized anti-M1 prime therapeutic antibody. Clin Antiinflamm Antiallergy Drugs. 2014;1(1):24–31. doi:10.2174/22127038114019990003
   Google Scholar
• Scheerens H, Putnam W, Zheng Y, et al. Treatment with MEMP1972A, an anti-M1 prime monoclonal antibody, reduced serum IgE in healthy volunteers and patients with allergic rhinitis. Am J Respir Crit Care Med. 2012;185:A6791.
   Google Scholar
• Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014;6(243):243ra85. doi:10.1126/scitranslmed.3008961
   PubMed Web of Science ®Google Scholar
• Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;138(6):1730–1732. doi:10.1016/j.jaci.2016.06.023
   PubMed Web of Science ®Google Scholar
• Shiung YY, Chiang CY, Chen JB, et al. An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.fc receptors. Immunobiology. 2012;217(7):676–683. doi:10.1016/j.imbio.2011.11.006
   PubMed Web of Science ®Google Scholar
• Chen JB, Ramadani F, Pang MOY, et al. Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody. Sci Rep. 2018;8(1):11548. doi:10.1038/s41598-018-29664-4
   PubMed Web of Science ®Google Scholar
• Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Gonzalez-Aveledo L. Biomarkers of treatment efficacy in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2018;50(1):5–9. doi:10.23822/EurAnnACI.1764-1489.24
   Web of Science ®Google Scholar
• Luu M, Bardou M, Bonniaud P, Goirand F. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2016;12(12):1503–1511. doi:10.1080/17425255.2016.1248403
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138(4):1051–1059.
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202–209. e5. doi:10.1016/j.jaci.2011.04.038
   PubMed Web of Science ®Google Scholar
• Metz M, Torene R, Kaiser S, et al. Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. Allergy. 2019;74(1):141–151. doi:10.1111/all.13547
   Web of Science ®Google Scholar
• Staubach P, Metz M, Chapman-Rothe N, et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–1144. doi:10.1111/all.12870
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(3):925.
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi:10.1056/NEJMoa1215372
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109. doi:10.1016/j.jaci.2013.05.013
   PubMed Web of Science ®Google Scholar
• Hide M, Igarashi A, Yagami A, et al. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in japanese patients: subgroup analysis of the phase 3 POLARIS study. Allergol Int. 2018;67(2):243–252.
   Web of Science ®Google Scholar
• Aubin F, Avenel-Audran M, Jeanmougin M, et al. Omalizumab in patients with severe and refractory solar urticaria: a Phase II multicentric study. J Am Acad Dermatol. 2016;74(3):574–575. doi:10.1016/j.jaad.2015.11.021
   Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi:10.1056/NEJMoa1215372
   PubMed Web of Science ®Google Scholar